RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics Symposium

Core Insights - GH Research PLC (NASDAQ:GHRS) is recognized as one of the 7 most promising psychedelic stocks according to hedge funds [1] - RBC Capital has raised its price target for GHRS to $40 from $33, maintaining an Outperform rating, citing increased optimism about the company's long-term sales potential, particularly for GH001 [2] - The FDA lifted the clinical hold on GH001, allowing U.S. patient enrollment and advancing global development plans, with a key Phase 3 program expected to launch in 2026 [3] Company Overview - GH Research PLC is a biotech company focused on developing innovative psychedelic-derived therapies aimed at treating mental health disorders through rigorous clinical research and evidence-based approaches [4] Clinical Developments - Phase 2b results for GH001 showed that 73% of patients maintained remission at six months with infrequent dosing, and 57.5% experienced remission by Day 8, indicating its potential as a transformative therapy for treatment-resistant depression [3]